DexCom, Inc.

NASDAQ:DXCM

Medical - Devices

Healthcare
$82.52 +1.27%

+$0.90 today

Market cap
$30.78B
Beta
1.44
P/E (TTM)
29.9
EPS (TTM)
$2.42
52W Low $54.11High $89.98

Volume 4.25M

Average 5.43M

DXCM Interest Expense

Cost of servicing the company's debt during the period.

DexCom, Inc.NASDAQ: DXCM

Interest Expense · Q2 FY2026 · quarter ended Jun 2026

Interest expense declines year over year

Q2 FY2026 interest expense of $3M fell 36.2% year over year, behind the -21.1% change in trailing-twelve-month interest expense. Sequentially, it fell 3.2% from the prior quarter. Over 3 fiscal years it compounded at -0.5% a year.

Context

  • Interest expense amounted to 0.4% of revenue in FY2025, unchanged from a year earlier.
  • Interest expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -36.2% toward the trailing-twelve-month pace of -21.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$3M-3.2% QoQ
Last fiscal yearDec 2025
$18.3M-3.7% YoY
LTMJun 2026
$15M-21.1% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-36.2%——
1 year-3.7%——
3-year CAGR-0.5%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
18.3M USD
Year-over-year change
-3.7%
4-year CAGR
-0.7%

Interest Expense vs competitors

How DXCM compares with its peers on the latest reported figures

  • DXCM's LTM Jun 2026 interest expense of $15M is the 2nd highest of the 7 companies compared; the peer median is $4.61M.
  • Its year-over-year change of -21.1% is the 4th highest of 5, against a peer median of +24.1%.
  • Interest expense amounts to 0.3% of revenue for DXCM, versus a peer median of 1.4%.
DXCM Competitors Peer median
Interest Expense for DXCM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PODDInsulet CorporationLTM Jun 2026$63.4M +27.3%+30.3%2.1%
DXCMDexCom, Inc.LTM Jun 2026$15M -21.1%-0.5%0.3%
TNDMTandem Diabetes Care, Inc.LTM Mar 2026$8.31M +20.8%+8.4%0.8%
SENSSenseonics Holdings, Inc.LTM Mar 2026$4.71M -39.7%-35.8%11.6%
DRIODarioHealth Corp.LTM Mar 2026$4.5M +3844.7%+7.8%21.2%
MMEDMiniMed Group, Inc. Common StockLTM Jul 2026$0 ——0.0%
BBNXBeta Bionics, Inc.LTM Mar 2026$0 ——0.0%
MMEDVMiniMed Group, Inc.—— ———
Peer median (excluding DXCM) $4.61M+24.1%+8.1%1.4%

Competitors are the stored peer set for DXCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.45B2.91B3.62B4.03B4.66B
Cost of Revenue768M1.03B1.33B1.59B1.86B
Gross Profit1.68B1.88B2.29B2.44B2.8B
Gross Margin68.6%64.7%63.2%60.5%60.1%
Research & Development604.2M484.2M505.8M552.4M599.1M
Selling, General & Admin810.5M1.01B1.19B1.29B1.29B
Operating Expenses1.41B1.49B1.69B1.84B1.89B
Depreciation & Amortization102M155.9M186M217.7M251.8M
EBITDA377.6M565.3M916.7M945.7M1.36B
EBITDA Margin15.4%19.4%25.3%23.4%29.1%
Operating Income265.8M391.2M597.7M600M911.8M
Operating Margin10.9%13.4%16.5%14.9%19.6%
Interest Income1.7M23.8M135M134.2M112.7M
Interest Expense18.8M18.6M20.3M19M18.3M
Other Income / Expenses(9M)(400K)112.7M109M176.6M
Income Before Tax256.8M390.8M710.4M709M1.09B
Pre-Tax Margin10.5%13.4%19.6%17.6%23.3%
Income Tax Expense39.9M49.6M168.9M132.8M252.1M
Net Income216.9M341.2M541.5M576.2M836.3M
Net Margin8.9%11.7%14.9%14.3%17.9%
EPS (Basic)0.560.881.441.462.14
EPS (Diluted)0.510.801.301.422.09
Weighted Avg Shares386.9M389.4M386M404.63M390.2M
Weighted Avg Shares (Diluted)428.8M427.5M425.5M412.7M405.5M

DexCom, Inc.

NASDAQ:DXCM

Intrinsic Alpha fair value

Locked

Current Price

$82.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.